

CENTER FOR DRUG EVALUATION AND RESEARCH

Application Number 20-323/S-021

PHARMACOLOGY REVIEW(S)

Electronic Mail Message

Date: 1/18/00 3:33:01 PM
From: Krishan Raheja
Subject: NDA 20-323/S021

(RAHEJA)

Diane,

There are no P/T issues and concerns about labeling.

Krishan

NDA 20-323/S-021

Vivelle® (estradiol transdermal system) 0.0375, 0.05, 0.75, 0.1 mg/day

Novartis Pharmaceutical Corporation

Pharmacology Review

No Pharmacology issues were presented in this application. No Pharmacology review was performed.

**APPEARS THIS WAY
ON ORIGINAL**